CLEARSIDE Secures Canadian Approval for XIPERE Amid Plunge in Stock and Mounting Losses
Introduction
CLEARSIDE BIOMEDICAL INC (Nasdaq: CLSD) is a biopharmaceutical company headquartered in Alpharetta, Georgia, that specializes in delivering therapies to the back of the eye via the suprachoroidal space (SCS). Founded in 2012, the company developed the proprietary SCS Microinjector®, which enables targeted, in-office, non-surgical injections to treat retinal and choroidal diseases.
Corporate Structure
As of 2025, CLEARSIDE employs between 11 and 50 professionals with expertise in ophthalmology, drug delivery technology, regulatory affairs, and commercial operations. The company's patented SCS Microinjector® platform has been used for over 10,000 injections, demonstrating its clinical and commercial capabilities in suprachoroidal administration.
Ophthalmology by CDC
Recent Developments and News
On July 23, 2025, Health Canada approved XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in uveitic macular edema. XIPERE is also approved by the U.S. Food and Drug Administration and is currently commercialized in the United States by Bausch + Lomb. In Greater China, South Korea, Australia, New Zealand, India, and ASEAN countries, Arctic Vision holds the license to develop and market the suspension under the name ARCATUS™.
The company's lead investigational asset, CLS-AX (axitinib injectable suspension), is classified as Phase 3 ready for the treatment of neovascular age-related macular degeneration (wet AMD).
Financial and Strategic Analysis
According to the quarterly report filed on November 14, 2025 (Form 10-Q for the period ended September 30, 2025), CLEARSIDE reported trailing twelve-month revenue of approximately USD 4.17 million and a net loss of USD 27.71 million (EPS: – 5.11). As of the most recent balance sheet, cash and cash equivalents were reported at USD 9.38 million. Research and development remain significant expenditures, with ongoing clinical programs contributing to R&D costs.
On November 24, 2025, the company's stock price closed at USD 0.8175, representing a 69.94% decline over the prior year. Daily trading volume on that date reached 479,868 shares. This stock price decrease reflects cash burn and the need for additional financing to support pipeline development and commercial activities for XIPERE. Management has indicated plans to pursue strategic collaborations or capital raises to extend the cash runway into 2026.
Market Position and Industry Context
CLEARSIDE positions itself in the suprachoroidal delivery segment within ophthalmic therapeutics, targeting posterior eye diseases. Its SCS injection technology provides a different approach compared to intravitreal and periocular injections, possibly reducing off-target effects. Competitors in the ocular drug delivery space include companies developing sustained-release intravitreal implants and gene therapies for retinal disorders. Regulatory approvals in multiple jurisdictions support CLEARSIDE’s platform, while commercial success will rely on wider adoption by retina specialists and continued demonstration of clinical benefits.
TL;DR
On July 23, 2025, CLEARSIDE received Health Canada approval for XIPERE in uveitic macular edema. The company reported a net loss of USD 27.71 million for the twelve months ending September 30, 2025, with USD 9.38 million in cash. Shares closed at USD 0.8175 on November 24, 2025. XIPERE commercialization in partnership with Bausch + Lomb continues, while CLS-AX is prepared for Phase 3 studies. Additional funding is anticipated to support operations into 2026.